Olsson L, Ebbesen P
J Natl Cancer Inst. 1979 Mar;62(3):623-7. doi: 10.1093/jnci/62.3.623.
Young female AKR mice made leukemic by iv inoculation of 10(3) spontaneous AKR thymoma cells were treated with repeated injections of irradiated cells from the same tumor. Treatment began 1 day after injection of the viable cells. The cytotoxicity of sera and lymphoid cells from healthy mice immunized with lymphoma cells from either treated or nontreated mice with leukemia grafts revealed that the tumor cells could be subdivided into four distinct antigenic types. One type (clone A) accounted for about 97% of the lymphoma cells in each mouse with spontaneous leukemia, whereas the remaining 3% were subdivided into three other distinct antigenic types (clones B, C, and D). Lymphoma cells from treated mice with grafted leukemia were never clone A type but either clone B, C, or D type. Repeated sc injections of 10(7) irradiated cells from spontaneous AKR thymomas induced from 15 to 34% cure in mice with grafts of leukemia cells. Treatment with only clone A induced about 32% cure, whereas treatment with clone B, C, or D had no beneficial effect. Treatment with 10(7) cells each of clone A plus clone B gave 33% cure; clone A plus clone B plus clone C, 45%; and all four clones cured 92% of the mice with leukemia grafts. The efficiency of immunotherapy may be influenced by the natural clonality of the tumor to be treated.
通过静脉注射10³个自发的AKR胸腺瘤细胞使年轻雌性AKR小鼠患白血病，然后用来自同一肿瘤的经辐照细胞重复注射进行治疗。治疗在注射活细胞后1天开始。用来自患有白血病移植瘤的已治疗或未治疗小鼠的淋巴瘤细胞免疫的健康小鼠的血清和淋巴细胞的细胞毒性表明，肿瘤细胞可细分为四种不同的抗原类型。一种类型（克隆A）在每只患有自发白血病的小鼠的淋巴瘤细胞中约占97%，而其余3%细分为其他三种不同的抗原类型（克隆B、C和D）。患有移植性白血病的已治疗小鼠的淋巴瘤细胞从未是克隆A型，而是克隆B、C或D型。重复皮下注射10⁷个来自自发AKR胸腺瘤的经辐照细胞，可使患有白血病细胞移植瘤的小鼠的治愈率达到15%至34%。仅用克隆A治疗可诱导约32%的治愈率，而用克隆B、C或D治疗则没有有益效果。用克隆A加克隆B各10⁷个细胞治疗的治愈率为33%；克隆A加克隆B加克隆C为45%；所有四种克隆可治愈92%的患有白血病移植瘤的小鼠。免疫疗法的疗效可能受待治疗肿瘤的自然克隆性影响。
